Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s004010050721, but it redirected us to https://link.springer.com/article/10.1007/s004010050721. The analysis below is for the second page.

Title[redir]:
bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status | Acta Neuropathologica
Description:
bcl-2 protein expression was characterized in a series of 58 astrocytomas from 21 pediatric and 37 adult patients. As part of a continuing attempt to define relevant prognostic factors which may predict clinical outcome, we have determined the impact of bcl-2 accumulation in malignant astrocytes on the length of patient survival. Aberrant overexpression of bcl-2 protein in tumor cells was detected in 57% (12 of 21) of pediatric and 73% (27 of 37) of the adult cases. Among pediatric patients, the median survival in months showed no relationship with the incidence of bcl-2-positive tumors. Among the adult patients, a favorable prognostic indicator was low-tumor grade (P = 0.05). bcl-2-positive tumors occurred with similar frequencies in WHO grades III and IV of malignancy. When bcl-2 expression in tumor cells was tested as a variable to predict for patient survival, the 6 patients without bcl-2 expression among 23 adult patients with grade IV tumors had a shorter median survival. The same 58 tumors had been previously analyzed for alterations of p53: 4 pediatric and 16 adult tumors had p53 gene mutations. There was no significant difference in median survival related to p53 gene status. There was no relationship between bcl-2 expression and p53 gene status: approximately equal numbers of tumors with either wild-type or mutant p53 were bcl-2 negative or bcl-2 positive. bcl-2 expression is high (40–100%) among other tumors of the central nervous system which also show low malignant potential. Up-regulation of bcl-2 in malignant astrocytes or constitutive expression in some tumor types may be a factor leading to a more favorable clinical outcome.

Matching Content Categories {πŸ“š}

  • Education
  • Science
  • TV

Content Management System {πŸ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We're unsure if the website is profiting.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {πŸ”}

bcl, article, expression, survival, tumors, gene, patients, cancer, york, privacy, cookies, content, adult, access, usa, information, publish, research, search, protein, astrocytomas, patient, status, pediatric, prognostic, tumor, university, center, data, log, journal, acta, newcomb, bhalla, parrish, clinical, outcome, malignant, median, related, discover, springer, optional, analysis, personal, parties, policy, find, track, neuropathologica,

Topics {βœ’οΈ}

month download article/chapter subtype-specific prognostic impact kaplan cancer center p53 gene status low-tumor grade bcl-2 protein expression bcl-2-positive tumors occurred p53 gene mutations full article pdf privacy choices/manage cookies favorable prognostic indicator cell cycle arrest median survival related favorable clinical outcome bcl-2 negative shorter median survival european economic area scope submit manuscript approximately equal numbers central nervous system cancer her2-positive conditions privacy policy predict clinical outcome check access instant access related subjects bcl-2 protein bcl-2-positive tumors accepting optional cookies bcl-2 expression article log journal finder publish acta neuropathol 94 grade iv tumors article newcomb article cite constitutive expression tumor cells tumor types median survival bcl-2 positive mutant p53 staten island privacy policy personal data york university patient survival high miller department

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status
         description: bcl-2 protein expression was characterized in a series of 58 astrocytomas from 21 pediatric and 37 adult patients. As part of a continuing attempt to define relevant prognostic factors which may predict clinical outcome, we have determined the impact of bcl-2 accumulation in malignant astrocytes on the length of patient survival. Aberrant overexpression of bcl-2 protein in tumor cells was detected in 57% (12 of 21) of pediatric and 73% (27 of 37) of the adult cases. Among pediatric patients, the median survival in months showed no relationship with the incidence of bcl-2-positive tumors. Among the adult patients, a favorable prognostic indicator was low-tumor grade (P = 0.05). bcl-2-positive tumors occurred with similar frequencies in WHO grades III and IV of malignancy. When bcl-2 expression in tumor cells was tested as a variable to predict for patient survival, the 6 patients without bcl-2 expression among 23 adult patients with grade IV tumors had a shorter median survival. The same 58 tumors had been previously analyzed for alterations of p53: 4 pediatric and 16 adult tumors had p53 gene mutations. There was no significant difference in median survival related to p53 gene status. There was no relationship between bcl-2 expression and p53 gene status: approximately equal numbers of tumors with either wild-type or mutant p53 were bcl-2 negative or bcl-2 positive. bcl-2 expression is high (40–100%) among other tumors of the central nervous system which also show low malignant potential. Up-regulation of bcl-2 in malignant astrocytes or constitutive expression in some tumor types may be a factor leading to a more favorable clinical outcome.
         datePublished:
         dateModified:
         pageStart:369
         pageEnd:375
         sameAs:https://doi.org/10.1007/s004010050721
         keywords:
            Key words bcl-2
            Astrocytomas
            Survival
            p53 tumor suppressor gene
            Prognosis
            Pathology
            Neurosciences
         image:
         isPartOf:
            name:Acta Neuropathologica
            issn:
               1432-0533
               0001-6322
            volumeNumber:94
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:E. W. Newcomb
               affiliation:
                     name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
                     address:
                        name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sandhya K. Bhalla
               affiliation:
                     name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
                     address:
                        name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Clarissa L. Parrish
               affiliation:
                     name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
                     address:
                        name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Roberta L. Hayes
               affiliation:
                     name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA
                     address:
                        name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA, , IS
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Henry Cohen
               affiliation:
                     name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA
                     address:
                        name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas C. Miller
               affiliation:
                     name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
                     address:
                        name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status
      description: bcl-2 protein expression was characterized in a series of 58 astrocytomas from 21 pediatric and 37 adult patients. As part of a continuing attempt to define relevant prognostic factors which may predict clinical outcome, we have determined the impact of bcl-2 accumulation in malignant astrocytes on the length of patient survival. Aberrant overexpression of bcl-2 protein in tumor cells was detected in 57% (12 of 21) of pediatric and 73% (27 of 37) of the adult cases. Among pediatric patients, the median survival in months showed no relationship with the incidence of bcl-2-positive tumors. Among the adult patients, a favorable prognostic indicator was low-tumor grade (P = 0.05). bcl-2-positive tumors occurred with similar frequencies in WHO grades III and IV of malignancy. When bcl-2 expression in tumor cells was tested as a variable to predict for patient survival, the 6 patients without bcl-2 expression among 23 adult patients with grade IV tumors had a shorter median survival. The same 58 tumors had been previously analyzed for alterations of p53: 4 pediatric and 16 adult tumors had p53 gene mutations. There was no significant difference in median survival related to p53 gene status. There was no relationship between bcl-2 expression and p53 gene status: approximately equal numbers of tumors with either wild-type or mutant p53 were bcl-2 negative or bcl-2 positive. bcl-2 expression is high (40–100%) among other tumors of the central nervous system which also show low malignant potential. Up-regulation of bcl-2 in malignant astrocytes or constitutive expression in some tumor types may be a factor leading to a more favorable clinical outcome.
      datePublished:
      dateModified:
      pageStart:369
      pageEnd:375
      sameAs:https://doi.org/10.1007/s004010050721
      keywords:
         Key words bcl-2
         Astrocytomas
         Survival
         p53 tumor suppressor gene
         Prognosis
         Pathology
         Neurosciences
      image:
      isPartOf:
         name:Acta Neuropathologica
         issn:
            1432-0533
            0001-6322
         volumeNumber:94
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:E. W. Newcomb
            affiliation:
                  name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
                  address:
                     name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sandhya K. Bhalla
            affiliation:
                  name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
                  address:
                     name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Clarissa L. Parrish
            affiliation:
                  name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
                  address:
                     name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Roberta L. Hayes
            affiliation:
                  name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA
                  address:
                     name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA, , IS
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Henry Cohen
            affiliation:
                  name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA
                  address:
                     name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas C. Miller
            affiliation:
                  name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
                  address:
                     name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Acta Neuropathologica
      issn:
         1432-0533
         0001-6322
      volumeNumber:94
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
      address:
         name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
         type:PostalAddress
      name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
      address:
         name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
         type:PostalAddress
      name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
      address:
         name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
         type:PostalAddress
      name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA
      address:
         name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA, , IS
         type:PostalAddress
      name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA
      address:
         name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA, , US
         type:PostalAddress
      name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
      address:
         name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:E. W. Newcomb
      affiliation:
            name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
            address:
               name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
               type:PostalAddress
            type:Organization
      name:Sandhya K. Bhalla
      affiliation:
            name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
            address:
               name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
               type:PostalAddress
            type:Organization
      name:Clarissa L. Parrish
      affiliation:
            name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211
            address:
               name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
               type:PostalAddress
            type:Organization
      name:Roberta L. Hayes
      affiliation:
            name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA
            address:
               name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA, , IS
               type:PostalAddress
            type:Organization
      name:Henry Cohen
      affiliation:
            name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA
            address:
               name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA, , US
               type:PostalAddress
            type:Organization
      name:Douglas C. Miller
      affiliation:
            name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA
            address:
               name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
               type:PostalAddress
            type:Organization
PostalAddress:
      name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
      name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
      name:New York University Medical Center and the Kaplan Cancer Center, 550 First Avenue, New York, NY 10016, USA Tel.: 1-212-263-8757; Fax: 1-212-263-8211, , US
      name:Department of Medicine, Staten Island University Hospital, Nalitt Institute for Cancer, Staten Island, NY 10305, USA, , IS
      name:Department of Environmental Medicine, New York University and General Clinical Research Center, New York, NY 10016, USA, , US
      name:Division of Neuropathology, New York University Medical Center, New York, NY 10016, USA, , US
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {πŸ”—}(85)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • Prism.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {πŸ“¦}

  • Crossref

3.71s.